Icahn School of Medicine at Mount Sinai

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).

708 total trials 163 currently recruiting 423 completed early-phase tilt top decile by trial count

Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.

Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.

Top-decile sponsor footprint

Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

708 total, page 10 of 15

COMPLETED Phase 2

Secukinumab for Treatment of Atopic Dermatitis

NCT02594098

COMPLETED NA

Self-directed Video Versus Instructor-based Neonatal Resuscitation Training

NCT01847911

COMPLETED NA

Family-based Approach to Promotion of Health - FAMILIA (Project 2)

NCT02481401

COMPLETED Early Phase 1

Autonomic Neuropathy, GI Motility, and Inflammation in HIV

NCT02850276

COMPLETED NA

Family-based Approach to Promotion of Health - FAMILIA (Project 1)

NCT02343341

TERMINATED Phase 2

A Study of Secukinumab for the Treatment of Alopecia Areata

NCT02599129

COMPLETED NA

Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia

NCT02334683

TERMINATED NA

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

NCT02568189

COMPLETED NA

Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease

NCT02560168

COMPLETED

Optimizing Postoperative Cognition the Elderly

NCT02650687

COMPLETED Phase 2

Targeting Platelets in Chronic HIV Infection

NCT02578706

COMPLETED

Large Scale Cerebral Oximetry During Sinus Endoscopy

NCT02692794

COMPLETED

Non Invasive Neuromonitoring After Cardiac Arrest

NCT02575196

COMPLETED NA

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

NCT03119363

COMPLETED

Mitochondrial Dysfunction and Disease Progression

NCT02549703

COMPLETED Phase 1

The Effects of Ondansetron on Brain Function

NCT02460341

COMPLETED NA

Trajectory of Recovery in the Elderly

NCT02275026

COMPLETED Phase 4

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

NCT02270242

COMPLETED

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

NCT02427204

COMPLETED

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512

TERMINATED

Biomarkers of Liver Fibrosis

NCT02438917

COMPLETED Phase 2

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

NCT02397889

COMPLETED

Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment

NCT02473419

COMPLETED

The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair

NCT02502838

COMPLETED

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

NCT02362659

COMPLETED NA

STRIPES Study: Study To Reduce Infection Post cEsarean Section

NCT02402907

COMPLETED Phase 3

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

NCT02325466

COMPLETED NA

Asthma Mobile Health Application 2.0

NCT03248869

COMPLETED

NICU-HEALTH (Hospital Exposures and Long-Term Health)

NCT01963065

COMPLETED Phase 1

Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department

NCT02399969

COMPLETED NA

Self-injection and Self-management

NCT02417493

COMPLETED NA

Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients

NCT02397876

COMPLETED

Malnutrition Associated With Complications After Ileostomy Reversal

NCT03909542

COMPLETED NA

Neuroprotection in Patients Undergoing Aortic Valve Replacement

NCT02389894

COMPLETED Phase 1

Treatment of Actinic Keratoses (AK) on the Face

NCT02411851

COMPLETED NA

Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life

NCT02322307

COMPLETED

Minimally Invasive Surgery (MIS) for Spine Metastases

NCT02367378

COMPLETED Phase 4

Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?

NCT02369510

COMPLETED NA

Adult Liver Transplant Enhanced Care

NCT02320422

COMPLETED NA

Supporting Asthma Management Behaviors in Aging Adults

NCT02316223

COMPLETED NA

Precision IFX: Using a Dashboard to Individualize Infliximab Dosage

NCT02624037

COMPLETED

Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood

NCT02718573

COMPLETED NA

Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis

NCT02467530

TERMINATED NA

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

NCT02363647

TERMINATED

Neurodevelopmental Outcomes of Preterm and Term Children

NCT02309697

COMPLETED

Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease

NCT02364778

COMPLETED

Psychosocial Risks in Liver Transplant Recipients

NCT02826460

COMPLETED Phase 2

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

NCT02513199

COMPLETED Phase 1

Foley Labor Induction Trial at Term and in PROM

NCT02098421

COMPLETED NA

Genetic Testing to Understand and Address Renal Disease Disparities

NCT02234063

← Previous Page 10 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 81
Phase 3 21
Phase 4 67

What is open in the Icahn School of Medicine at Mount Sinai pipeline

163 recruiting of 708 indexed (23% open); 423 completed (60%).

Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide

Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Icahn School of Medicine at Mount SinaiSanofiWeill Medical College of Cornell UniversityUniversity of MiamiThe Cleveland ClinicClemson UniversityLiberating TechnologiesRahul AggarwalSequenom
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 708 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

What to do with this Icahn School of Medicine at Mount Sinai page

708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.

  • 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.